Nexplanon Lawsuit: What Exists, What Settled, and What Doesn’t Pay You
Questions about this case?
AI Legal Assistant · free · answers in seconds · general information, not legal advice
There are two different things behind the “nexplanon lawsuit” headlines. One is a small group of injury claims over the birth control implant, which Organon settled confidentially on March 12, 2026. The other is an investor fraud case in New Jersey federal court over how Organon sold and described Nexplanon. As of October 2026 there is no class action for implant users, no Nexplanon settlement fund and no claim form.
Editorially Reviewed — Content reviewed for accuracy using published legal research, government data, and verified court records. See our methodology
Reviewed by Leonard Goldberg, Editor · Last updated
What the Lawsuits Say
Injury claims. Nexplanon and its predecessor Implanon are etonogestrel implants placed under the skin of the upper arm. Individual users have sued Merck, which originally sold the implants, over injuries. Organon, which took over the product when it was spun off from Merck, must cover Merck’s liability for these cases. The FDA label carries a boxed warning on complications from improper insertion and removal. It also warns that an implant can migrate into blood vessels, including the vessels of the lungs. Surgery may be needed to remove it.
Investor claims. Shareholders allege that Organon overstated how long Nexplanon would stay protected from generic competition, saying “through 2027 at the earliest.” They also allege the company misled investors about its dividend. In October 2025 Organon disclosed that U.S. wholesalers had been asked to buy more Nexplanon than they needed in several quarters, and the amended investor complaint added those allegations. These are allegations, not findings of a court.
Case Details
Injury cases (per Organon’s SEC filing for the quarter ended June 30, 2026): two filed Implanon product liability actions in the U.S. District Court for the Northern District of Ohio, 56 unfiled Implanon claims held under a tolling agreement, and one Nexplanon matter in California state court. Abroad, 19 cases were pending: seven over Implanon and twelve over Nexplanon. There is no multidistrict litigation (MDL).
Investor case: Hauser v. Organon & Co., No. 2:25-cv-05322, consolidated with Lerner v. Organon & Co., No. 25-cv-12983, in the U.S. District Court for the District of New Jersey before Judge Julien Xavier Neals. On March 6, 2026 Magistrate Judge Cari Fais consolidated the cases and appointed Teamsters Local 710 Pension Fund as lead plaintiff. Separately, the SEC opened an investigation after Organon’s voluntary self-disclosure on October 26, 2025.
Status: Injury Claims Settled, Investor Case Pending
For investors: the lead plaintiff filed an amended complaint on May 8, 2026 and later said it would file a second one. A court order of June 17, 2026 gives Organon 60 days to respond once that second complaint is filed or the request to file it is denied. As of October 2026 we found no ruling on the merits and no settlement. Source: Organon 10-Q.
Follow this case
There's no claim deadline yet. We'll email you if a settlement opens a claim period.
Who Could Be Affected
If you had Nexplanon or Implanon: you are not part of any class, because none has been filed for users. The injury claims are individual claims. If you believe an implant injured you, for example by migrating, breaking, or needing surgery to remove, any claim would be your own. Filing deadlines (statutes of limitations) vary by state and can be short. A licensed attorney in your state is the person to ask.
If you bought Organon stock: the proposed investor class covers people who bought Organon shares between November 3, 2022 and April 30, 2025. You do not need to sign up now. If the case settles, a court-appointed administrator sends notice, usually through brokers.
What This Pays — Honestly
For investors: the complaint seeks unspecified damages, and nothing is payable. Investor settlements pay per share based on when you bought and sold, never a flat amount. One practical factor: Organon agreed on April 26, 2026 to be acquired by Sun Pharma for $14.00 per share in cash. Organon says the deal is expected to close in early 2027. Pending lawsuits normally stay with the company after a buyout.
Nexplanon Litigation Timeline
- 1
October 27, 2025 — Wholesaler Findings Announced
Organon says an Audit Committee investigation found U.S. wholesalers were asked to buy more Nexplanon than they needed in quarters from 2022 to 2025. Its CEO resigns. The day before, Organon self-reported the matter to the SEC.
- 2
January 2026 — Label Revised
The FDA label, revised 01/2026, carries a boxed warning on improper insertion and removal, a REMS program, and approval for up to 5 years of use.
- 3
March 6, 2026 — Investor Suits Consolidated
The New Jersey federal court combines the Hauser and Lerner cases and appoints Teamsters Local 710 Pension Fund as lead plaintiff.
- 4
March 12, 2026 — Injury Claims Settled
Organon signs a Master Settlement Agreement: 56 plaintiffs and claimants release their claims for a confidential payment. There is no class and no claim form.
- 5
May 8, 2026 — Nexplanon Allegations Added
The amended investor complaint adds allegations about the wholesaler matter. On May 29 the lead plaintiff says it will file a second amended complaint.
- 6
As of October 2026 — No Consumer Payout
As of Organon’s 10-Q for the quarter ended June 30, 2026, the investor case was at the pleading stage, the SEC investigation was open, and one Nexplanon matter was pending in California state court. No fund and no claim form exist for implant users.
Three Things to Watch For
A well-known product name, injury ads and an investor case together leave plenty of room for confusion:
“Claim your Nexplanon settlement” forms
No public claim process exists. The March 2026 deal covered only named claimants who already had lawyers. A site that asks for your Social Security number or insurance details to “reserve your payment” is collecting data. Often it is a lead form that gets sold on.
“Nexplanon class action — you qualify” texts
There is no class action for implant users. Messages promising a fixed payout amount, or saying “the deadline is tomorrow,” are advertising, not court notices. Real settlement notices name the court, the case number and an administrator.
Investor “recovery” offers with a fee
If you held Organon stock, you may get calls offering to “recover your losses” for an upfront fee. The investor case has no settlement. If one comes, filing a claim with the administrator costs nothing.
Nexplanon Lawsuit — Questions People Actually Ask
Is there a Nexplanon class action lawsuit for people who had the implant?
No. As of Organon’s 10-Q for the quarter ended June 30, 2026, the injury cases are individual cases. Two Implanon actions are in the Northern District of Ohio and one Nexplanon matter is in California state court, per Organon’s SEC filing. There is no MDL and no class.
Was there a Nexplanon settlement?
Yes, but only a private one. On March 12, 2026 Organon signed a Master Settlement Agreement under which 56 plaintiffs and claimants release their claims for a confidential payment. Nobody else can file a claim under it.
What injuries are the implant claims about?
Organon’s filing does not list them. The FDA label warns of pain, nerve symptoms, bleeding, scarring and infection from insertion or removal. It also warns of migration into blood vessels, including those in the lungs, with symptoms such as chest pain, shortness of breath, cough or coughing blood. If you have those symptoms, see a doctor first.
Who is being sued — Merck or Organon?
The injury suits name Merck, which sold the implants before Organon was spun off. Under their separation agreement, Organon must cover Merck’s losses from these cases. The investor case names Organon and some of its officers.
What is the Organon investor lawsuit about?
Shareholders allege that Organon misled them about how long Nexplanon would be protected from generics, about the dividend, and about wholesaler sales. The proposed class bought shares between November 3, 2022 and April 30, 2025. Organon has not been found liable.
Does the Sun Pharma takeover end the lawsuits?
Not by itself. Organon agreed on April 26, 2026 to be acquired by Sun Pharma for $14.00 per share in cash, and shareholders approved the deal on July 23, 2026. Lawsuits against a company usually stay with it after an acquisition.
I have the implant now. Do I need to do anything?
No legal step is needed, because no claim process exists. Medically, the label tells providers to confirm by touch, right after insertion, that the implant is in the arm. It also warns that an implant inserted too deeply may be hard to feel and hard to remove. If you cannot feel yours, ask your provider.
I think an implant injured me. What should I keep?
Keep insertion and removal records, imaging reports, the lot number if you have it, and bills. State filing deadlines can be short, so talk to a licensed attorney soon. For estimates on other device cases, see our medical device lawsuit calculator.
Separate from this case: were you injured in the last 2 years?
Class-action payouts are fixed amounts through an administrator. A personal injury claim is a different case — and often worth far more. Free estimate, no obligation.
Related Consumer Brand Lawsuits
Medical Device Lawsuit Calculator
How injury claims over implants and devices are valued
Depo-Provera Lawsuit Calculator
Another contraceptive case, this one in a federal MDL
Open Class Action Settlements
Settlements currently taking claims, with deadlines
Settlement Payout Calculator
Estimate a per-person share of a class fund